menu
    • menu
    [{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Chlorpheniramine Maleate","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Ferrer BioPharma","sponsor":"Hospital CEMESA Cort\u00e9s, San Pedro Sula, Honduras","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Chlorpheniramine Maleate","moa":"Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dr. Ferrer BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Dr. Ferrer BioPharma \/ Hospital CEMESA Cort\u00e9s, San Pedro Sula, Honduras","highestDevelopmentStatusID":"9","companyTruncated":"Dr. Ferrer BioPharma \/ Hospital CEMESA Cort\u00e9s, San Pedro Sula, Honduras"},{"orgOrder":0,"company":"Dr. Ferrer BioPharma","sponsor":"Hospital CEMESA Cort\u00e9s, San Pedro Sula, Honduras","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Chlorpheniramine Maleate","moa":"Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dr. Ferrer BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Dr. Ferrer BioPharma \/ Hospital CEMESA Cort\u00e9s, San Pedro Sula, Honduras","highestDevelopmentStatusID":"9","companyTruncated":"Dr. Ferrer BioPharma \/ Hospital CEMESA Cort\u00e9s, San Pedro Sula, Honduras"},{"orgOrder":0,"company":"Brainfarma","sponsor":"Techtrials Pesquisa e Tecnologia Ltda | Pharmagenix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Chlorpheniramine Maleate","moa":"Histamine H1 receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"Brainfarma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brainfarma \/ Techtrials Pesquisa e Tecnologia Ltda | Pharmagenix","highestDevelopmentStatusID":"10","companyTruncated":"Brainfarma \/ Techtrials Pesquisa e Tecnologia Ltda | Pharmagenix"}]

    Find Clinical Drug Pipeline Developments & Deals for Chlorphenamine Maleate

    Menu

    Chlorphenamine Maleate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Ferrer BioPharma

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Dr. Ferrer BioPharma

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorpheniramine Maleate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Hospital CEMESA Cortés, San Pedro Sula, Honduras

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III

                            Details : Chlorpheniramine Maleate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 02, 2023

                            Lead Product(s) : Chlorpheniramine Maleate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Hospital CEMESA Cortés, San Pedro Sula, Honduras

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dr. Ferrer BioPharma

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Dr. Ferrer BioPharma

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorpheniramine Maleate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Hospital CEMESA Cortés, San Pedro Sula, Honduras

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I

                            Details : Chlorpheniramine Maleate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 08, 2022

                            Lead Product(s) : Chlorpheniramine Maleate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Hospital CEMESA Cortés, San Pedro Sula, Honduras

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Brainfarma

                            Brazil arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Brainfarma

                            Brazil arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorpheniramine Maleate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Techtrials Pesquisa e Tecnologia Ltda | Pharmagenix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold

                            Details : Chlorpheniramine Maleate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 12, 2016

                            Lead Product(s) : Chlorpheniramine Maleate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Techtrials Pesquisa e Tecnologia Ltda | Pharmagenix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bayer AG

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorpheniramine Maleate

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exploratory Study for Allergy Relief Onset

                            Details : Chlorpheniramine Maleate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 29, 2016

                            Lead Product(s) : Chlorpheniramine Maleate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth